186 related articles for article (PubMed ID: 10633781)
1. [Hepatogenic diabetes--the current concepts of its pathophysiology and therapy].
Siegel EG; Gallwitz B; Schmidt WE; Fölsch UR
Dtsch Med Wochenschr; 1999 Dec; 124(50):1530-5. PubMed ID: 10633781
[No Abstract] [Full Text] [Related]
2. [Novel therapy in type 2 diabetes: to regulate glucose metabolism naturally].
MMW Fortschr Med; 2005 Aug; 147(31-32):54-5. PubMed ID: 16128202
[No Abstract] [Full Text] [Related]
3. A gut response. The next generation of type 2 drugs.
Kordella T
Diabetes Forecast; 2004 Apr; 57(4):39-42. PubMed ID: 15119299
[No Abstract] [Full Text] [Related]
4. [Treatment of diabetes mellitus. New developments and hopes].
Verspohl EJ
Med Monatsschr Pharm; 2005 Jun; 28(6):193-202; quiz 203. PubMed ID: 15960421
[No Abstract] [Full Text] [Related]
5. Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes.
Nauck M
Diabet Med; 1996 Sep; 13(9 Suppl 5):S39-43. PubMed ID: 8894470
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter.
Larsen PJ; Holst JJ
Regul Pept; 2005 Jun; 128(2):97-107. PubMed ID: 15780429
[TBL] [Abstract][Full Text] [Related]
7. [A therapeutic option for type-2 diabetes. The incretion hormone GLP-1].
Göke B; Hoppe B; Konrad A; Schirra J
Pharm Unserer Zeit; 2002; 31(3):294-9. PubMed ID: 12071126
[No Abstract] [Full Text] [Related]
8. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
9. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients.
Seifarth C; Bergmann J; Holst JJ; Ritzel R; Schmiegel W; Nauck MA
Diabet Med; 1998 Jun; 15(6):485-91. PubMed ID: 9632123
[TBL] [Abstract][Full Text] [Related]
10. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.
Dupre J
Regul Pept; 2005 Jun; 128(2):149-57. PubMed ID: 15780434
[TBL] [Abstract][Full Text] [Related]
11. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.
Theodorakis MJ; Carlson O; Michopoulos S; Doyle ME; Juhaszova M; Petraki K; Egan JM
Am J Physiol Endocrinol Metab; 2006 Mar; 290(3):E550-9. PubMed ID: 16219666
[TBL] [Abstract][Full Text] [Related]
12. Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes.
Lugari R; Dell'Anna C; Ugolotti D; Dei Cas A; Barilli AL; Zandomeneghi R; Marani B; Iotti M; Orlandini A; Gnudi A
Horm Metab Res; 2000 Oct; 32(10):424-8. PubMed ID: 11069208
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
Nauck MA
Horm Metab Res; 2004; 36(11-12):852-8. PubMed ID: 15655719
[TBL] [Abstract][Full Text] [Related]
14. Are we closer to finding the treatment for type 2 diabetes mellitus in morbid obesity? Are the incretins the key to success?
Frezza EE
Obes Surg; 2004 Aug; 14(7):999-1005. PubMed ID: 15329192
[TBL] [Abstract][Full Text] [Related]
15. Gastric inhibitory polypeptide.
Brown JC
Monogr Endocrinol; 1982; 24():III-XI, 1-88. PubMed ID: 6214707
[No Abstract] [Full Text] [Related]
16. Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus.
McIntosh CH; Demuth HU; Kim SJ; Pospisilik JA; Pederson RA
Int J Biochem Cell Biol; 2006; 38(5-6):860-72. PubMed ID: 16442340
[TBL] [Abstract][Full Text] [Related]
17. [Gastrointestinal peptides among new therapeutic agents used in type 2 diabetes].
Efendic S; Bystedt T; Ostenson CG
Lakartidningen; 1999 Feb; 96(8):888-92. PubMed ID: 10089733
[TBL] [Abstract][Full Text] [Related]
18. GLP-1 effect upon the GPI/IPG system in adipocytes and hepatocytes from diabetic rats.
Márquez L; González N; Puente J; Valverde L; Villanueva-Peñacarrillo ML
Diabetes Nutr Metab; 2001 Oct; 14(5):239-44. PubMed ID: 11806463
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
[TBL] [Abstract][Full Text] [Related]
20. [Glucose intolerance in liver diseases].
Aoki Y
Nihon Rinsho; 2002 Jul; 60 Suppl 7():719-23. PubMed ID: 12238124
[No Abstract] [Full Text] [Related]
[Next] [New Search]